Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036262 | 0.84 | GRIN1 (0.40) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL2804798 | 0.79 | CACNA1B (0.37) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3028107 | 0.78 | ITGB2 (0.42) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3033572 | 0.77 | GRIN1 (0.43) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL29603907 | 0.77 | CACNA1B (0.39) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3042679 | 0.76 | PIK3CA (0.36) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL2786954 | 0.76 | PGR (0.38) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3033244 | 0.76 | GRIN1 (0.41) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3043842 | 0.74 | CACNA1B (0.37) | ITGB2ICAM1ITGALGRIN1GRIN2B | |
| SCHEMBL3014591 | 0.74 | SCN9A (0.40) | GRIN1GRIN2BCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2209373-B1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2209373-B1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2209373-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | ITGB2 1204/4885ICAM1 720/4885ITGAL 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.